At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 11, 2026 at 14:00 ET
BridgeBio Pharma presented positive interim Phase 3 FORTIFY trial results for BBP-418, an oral therapy for LGMD2I/R9, showing rapid and sustained efficacy across key endpoints including ambulation and biomarker improvements, with a safety profile comparable to placebo. Based on these results, the company plans to submit an NDA to the FDA in the first half of 2026, with a potential U.S. launch in late 2026 or early 2027. If approved, BBP-418 would be the first therapy for LGMD2I/R9 and potentially the first for any limb-girdle muscular dystrophy (LGMD) subtype.
- Positive interim Phase 3 FORTIFY trial results show BBP-418 improved ambulation (31-second advantage on 100MTT at 12 months vs. placebo) and reduced serum creatine kinase, with effects seen as early as 3 months.
- BBP-418 demonstrated consistent benefit across all prespecified subgroups (genotype, age, FVC) and achieved normalization of CK in 38.3% of patients after 12 months.
- Safety profile was favorable, with no treatment-related serious adverse events and no new safety signals.
- BridgeBio plans to submit an NDA to the FDA in the first half of 2026, with a potential U.S. launch in late 2026/early 2027.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access